Cinderella is predominantly interested in compounds and treatments that in preclinical research or other good reasons are regarded promising for clinical use. The activity and quality of these drugs should be such that their efficacy can be evaluated clearly in a short time period and in a small number of patients.
Inventors of stalled drugs/therapies have to be interested in sharing their invention with Cinderella on a not-for-profit base and to transfer all their rights and intellectual property to Cinderella Therapeutics.
Proposals will be evaluated by the Board of the Foundation in consultation with independent experts selected by the Board and the inventors of the proposed stepchild drug or therapy.
You can contact the Board by phone at +31 172 685 388 or send a message to email@example.com